Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alkaloids, Hydrogenated Ergot
2. Co-dergocrine
3. Dihydroergotoxin
4. Ergot Alkaloids, Hydrogenated
5. Hydrogenated Ergot Alkaloids
1. 11032-41-0
2. 6190-39-2
3. Dihydroergotamine Methanesulfonate Salt
4. (6ar,9r)-n-[(1s,2s,4r,7s)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic Acid
5. Smr001230668
6. Prestwick_746
7. Schembl40844
8. Mls002153175
9. Mls002207048
10. Chembl1396675
11. Hms2231h03
12. Hms3886k22
13. Dihydroergotamine For Peak Identification
14. D2633
15. Dihydroergotamine Methanesulfonate Salt, Powder
16. Q16633838
17. Z1544404034
18. Dihydroergotamine Mesilate, European Pharmacopoeia (ep) Reference Standard
19. Dihydroergotamine For Peak Identification, European Pharmacopoeia (ep) Reference Standard
20. Dihydroergotamine Mesylate, United States Pharmacopeia (usp) Reference Standard
21. (4r,7r)-n-[(1s,2s,4r,7s)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carboxamide; Methanesulfonic Acid
22. (6ar,9r)-n-((2r,5s,10as,10bs)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2h-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
23. (6ar,9r)-n-((2r,5s,10as,10bs)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2h-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide Methanesulfonate
24. (6ar,9r)-n-((2r,5s,10as,10bs)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8h-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide Methanesulfonate
25. 910882-41-6
Molecular Weight | 679.8 g/mol |
---|---|
Molecular Formula | C34H41N5O8S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 4 |
Exact Mass | 679.26758446 g/mol |
Monoisotopic Mass | 679.26758446 g/mol |
Topological Polar Surface Area | 181 Ų |
Heavy Atom Count | 48 |
Formal Charge | 0 |
Complexity | 1260 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Dihydroergotamine mesylate |
Active Ingredient | Dihydroergotamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/ml |
Market Status | Prescription |
Company | Paddock; Bedford Labs |
2 of 2 | |
---|---|
Drug Name | Dihydroergotamine mesylate |
Active Ingredient | Dihydroergotamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/ml |
Market Status | Prescription |
Company | Paddock; Bedford Labs |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?